Skip to content
Screener

Nuvation Bio NUVB Finite Lived Intangible Assets - Gross

Finite Lived Intangible Assets - Gross at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$30.36M—
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$20.94M—

Segments

By product

See full
Research And Development Service Revenue$500K—

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity0×-0.1×
Current ratio8.4×-1.0×

FAQ

What does finite lived intangible assets - gross mean?
This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.